Ventures

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

The Venous Stent is a new type of stent designed to help with conditions like deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). Unlike older stents, this one can adjust in length and has multiple parts, making it more flexible and better for the veins. It helps improve blood flow and healing in the veins, potentially reducing the need for long-term medication.

Haermonics addresses the challenge of complications after open heart surgery with a transformative solution. Excessive blood loss and clots post-surgery lead to numerous issues, including reoperations and cardiac tamponades, resulting in significant healthcare costs and loss of lives. The Haermonics Flush device offers a preventive approach by flushing the pericardial cavity after surgery, limiting blood loss and clot formation. By providing medical professionals with better patient status monitoring, Haermonics Flush empowers doctors to make more informed decisions, ultimately saving thousands of lives and billions in hospital costs.

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.